Mangoceuticals, Inc. (NASDAQ: MGRX) announced on February 3, 2025, an exclusive Master Distribution Agreement with Propre Energie, Inc. for Dermytol®, a clinically proven plant-based skincare treatment. Dermytol® is designed to improve skin tone and reduce hyperpigmentation, addressing dark spots, uneven skin tone, and acne scars.
Dermytol® utilizes a proprietary blend of clinically validated ingredients, including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera. In vitro studies demonstrated Dermytol® to be more effective at reducing melanin production and significantly less damaging to skin cells compared to Kojic acid.
This agreement grants Mangoceuticals exclusive rights to market, sell, and distribute Dermytol® across North and South America. The global plant-based skincare products market, valued at $789.75 million in 2023, is expected to grow to $1.62 billion by 2033, reflecting a robust 7.5% compound annual growth rate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.